Skip to main content
International Journal of Bipolar Disorders
Fig. 2 | International Journal of Bipolar Disorders

Fig. 2

From: NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial

Fig. 2

(Graph) Primary Endpoint for those infused with ketamine vs. placebo in phase I (n=22) and those who responded to ketamine in phase I and were randomized in phase II to receive either NRX-101 or lurasidone (n=17). Table depicts primary and secondary endpoints for those randomized in phase II (n=17).; *, P<0.05

Back to article page